Antral Injections of Botulinum A Toxin for the Treatment of Obesity

  1. Jens D. Rollnik, MD;
  2. Peter N. Meier, MD;
  3. Michael P. Manns, MD; and
  4. Michael Göke, MD
  1. Medical School Hannover; 30623 Hannover, Germany (Rollnik, Meier, Manns, Göke)

    The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

    •Include no more than 300 words of text, three authors, and five references

    •Type with double-spacing

    •Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

    Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

    Annals welcomes electronically submitted letters.

    TO THE EDITOR:

    Background: In Germany, approximately 50% of the population are overweight and 20% are obese (1). Overweight and obesity increase the risk for metabolic complications, arterial hypertension, cardiovascular diseases, and cancer (1). Long-term reduction of excess weight may improve …

    « Previous | Next Article »Table of Contents